AstraZeneca PLC (NASDAQ:AZN) announced a $15 billion investment in China through 2030 to expand manufacturing and R&D, strengthening capabilities in cell therapy and radioconjugates while deepening China-UK healthcare collaborations. The investment will enhance AstraZeneca’s pipeline across cancer, autoimmune, and hematological diseases, build on its acquisition of Gracell Biotechnologies, and grow its workforce in China beyond 20,000. Guggenheim reiterated a Buy rating on AstraZeneca PLC in anticipation of impressive fourth-quarter and 2025 financial results, expecting high single-digit revenue growth to reach $58.5 billion and double-digit EPS growth of $9.15 a share. Confidence is rising in AstraZeneca’s 2030 outlook as the company advances its pipeline to offset upcoming patent expirations for Imfinzi and Tagrisso.

Read more at Yahoo Finance: AstraZeneca PLC (AZN)’s $15B China Expansion Fuels Long-Term Growth Outlook